DE2922670C2 - Chewable dosage form - Google Patents
Chewable dosage formInfo
- Publication number
- DE2922670C2 DE2922670C2 DE19792922670 DE2922670A DE2922670C2 DE 2922670 C2 DE2922670 C2 DE 2922670C2 DE 19792922670 DE19792922670 DE 19792922670 DE 2922670 A DE2922670 A DE 2922670A DE 2922670 C2 DE2922670 C2 DE 2922670C2
- Authority
- DE
- Germany
- Prior art keywords
- active ingredients
- pharmaceutical form
- porous particles
- dosage form
- form according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002552 dosage form Substances 0.000 title description 4
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000004464 cereal grain Substances 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- -1 hard paraffins Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 240000000991 Eucalyptus amygdalina Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- QCNVFAQSXRNCES-UHFFFAOYSA-L S(=O)(=O)(O)C(C(=O)OCCCCCCCC)CC(=O)[O-].[Na+].[Na+].C(CCCCCCC)OC(C(CC(=O)[O-])S(=O)(=O)O)=O Chemical compound S(=O)(=O)(O)C(C(=O)OCCCCCCCC)CC(=O)[O-].[Na+].[Na+].C(CCCCCCC)OC(C(CC(=O)[O-])S(=O)(=O)O)=O QCNVFAQSXRNCES-UHFFFAOYSA-L 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical compound OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Die Erfindung betrifft eine Arzneiform gegen Erkrankungen des Mund- und Rachenraumes und der Atemwege, bestehend, aus einer kaubaren Matrix mit medikamentösen Wirkstoffen.The invention relates to a drug form against diseases of the mouth and throat and the Respiratory tract, consisting of a chewable matrix with active pharmaceutical ingredients.
Zur Behandlung von Erkrankungen des Mund- und Rachenraumes und der Atemwege werden üblicherweise Lutschbonbons und Pastillen verwendet, die nichtrezeptpflichtige Wirkstoffe, meist Pflanzenauszüge, enthalten. Nachteilig bei dieser Arzneiform ist, daß die Matrix im wesentlichen aus Zucker besteht, der kariesfördernd ist und von zuckerkranken Personen nicht eingenommen werden kann. Ferner besteht bei den meisten Patienten die Neigung, solche Pastillen und Bonbons zu zerbeißen, wodurch die Applikationsdauer verringert und durch kurzzeitige Überdosierung Schädigungen hervorgerufen werden können.For the treatment of diseases of the mouth and throat and the respiratory tract are usually Lozenges and lozenges are used that contain active ingredients that do not require a prescription, mostly plant extracts. The disadvantage of this drug form is that the matrix consists essentially of sugar, the is caries-promoting and cannot be taken by diabetic people. Furthermore, there is most patients have a tendency to chew such lozenges and candies, which increases the duration of the application reduced and damage can be caused by brief overdosing.
Kaubare Massen mit Arzneistoffen zur Pflege und Behandlung des Mund- und Rachenraumes sind in DE-OS 24 25 322, FR-PS 23 20 083 beschrieben. Zwar sind solche Arzneiformen verglichen mit Pastillen und dergleichen im Hinblick auf die Arzneimittelverabreichung vorteilhafter, die Wirkstoffabgaberaten werden jedoch dabei nicht wesentlich reduziert, so daß sie nicht als ein Wirkstoff-Langzeitdepot angesehen werden können.Chewable masses with medicinal substances for the care and treatment of the mouth and throat are in DE-OS 24 25 322, FR-PS 23 20 083 described. It is true that such dosage forms are compared with lozenges and the like become more advantageous in terms of drug administration, the drug delivery rates become but not significantly reduced, so that they are not regarded as a long-term active ingredient depot can.
Der vorliegenden Erfindung liegt daher die Aufgabe zugrunde, eine kaubare Arzneiform zu entwickeln, die über einen wesentlich längeren Zeitraum hinweg die Wirkstoffe möglichst gleichmäßig in den Mund- und Rachenraum abgibtThe present invention is therefore based on the object of developing a chewable dosage form which the active ingredients as evenly as possible in the mouth and over a much longer period of time Throat area gives off
Es hat sich nun gezeigt, daß sich diese Aufgabe gemäß Anspruch 1 in technisch fortschrittlicher Weise lösen läßt, wenn die Wirkstoffe in feinteiligen, porösen Teilchen mit einer Teilchengröße von 0,1 bis 100 μιτι eingelagert sind. Die vorteilhaften Weiterbildungen der erfindungsgemäßen Arzneiform sind in den Unteran-Sprüchen 2 und 3 beschrieben.It has now been shown that this problem can be solved according to claim 1 in a technically advanced manner lets when the active ingredients μιτι in finely divided, porous particles with a particle size of 0.1 to 100 are stored. The advantageous developments of the dosage form according to the invention are in the sub-claims 2 and 3.
Als kaubare Matrizes werden an sich bekannte Substanzen herangezogen, z. B. hochmolekulare, natürliche oder künstliche Harze und Wachse, Kautschuk, Piccolit-Harz, Hartparaffine, Bienenwachs, Wollfett,Substances known per se are used as chewable matrices, e.g. B. high molecular weight, natural or artificial resins and waxes, rubber, piccolite resin, hard paraffins, beeswax, wool fat,
IU Carnaubawachs, Walrat und Candeililawachs. Die Matrix kann auch übliche Zusatzstoffe enthalten, z. B. Geschmack- und Aromastoffe. Als Geschmackstoffe können Zuckeraustauschstoffe wie Sorbit, und Süßstoffe wie Saccharin, verwendet werden. Als Aromastoffe sindIU carnauba wax, whale rat and candeilila wax. The matrix can also contain conventional additives, e.g. B. Flavors and aromas. Sugar substitutes such as sorbitol, and sweeteners can be used as flavorings such as saccharin, can be used. As flavors are
z. B. Pfefferminzöl, Spearmintöl, Anisö!, Eukalyptusöl, Gewürznelköl, Vanillearoma und Zimtaroma geeignet.z. B. peppermint oil, spearmint oil, aniseed, eucalyptus oil, Clove oil, vanilla flavor and cinnamon flavor are suitable.
Die erfindungsgemäße Arzneiform kann in an sichThe pharmaceutical form according to the invention can in itself
bekannter Weise durch Verkneten der Bestandteile hergestellt werden. Zur Erzielung einer gleichmäßigen Dosierung während der Kauzeit sowie zur Reduktion der Wirkstoffabgaberaten werden die Wirkstoffe vor dem Kne*sn in feinteili^e "oröss Teilchen ein^els^^rt ' * vorzugsweise in anorganische Teilchen wie Aluminiumhydroxid. Aluminiumoxid, Magnesiumoxid, Silicium-be prepared in a known manner by kneading the ingredients. To achieve a uniform Dosage during the chewing time as well as to reduce the drug release rates, the active ingredients are before dem Kne * sn in finely divided particles a ^ els ^^ rt '* preferably in inorganic particles such as aluminum hydroxide. Aluminum oxide, magnesium oxide, silicon
dioxyd und Calciumcarbonat oder in feingemahlene cellulosehaltige Gerüstsubstanzen aus Getreidekörnern oder Stärke. Die porösen Teilchen können z. B. durch Tränken mit der Wirkstofflösung und anschließendem Entzug des Lösungsmittels durch Trocknen bzw.dioxide and calcium carbonate or finely ground cellulose-containing structural substances from cereal grains or starch. The porous particles can e.g. B. by Soaking with the active ingredient solution and subsequent removal of the solvent by drying or
Verdampfen mit dem Wirkstoff beladen werden. Diese Beladung kann auch durch Verpressen des Wirkstoffpulvers
mn dem Pulver aus porösen Teilchen und anschließendem Vermählen des Preßlings erfolgen.
Zur Erleichterung des Transports der Wirkstoffe und damit zur Steigerung ihrer Wirkung können der
Kaumasse Tenside zugeführt werden, die die Oberflächenspannung des erkrankten Gewebes herabsetzen.
Solche magen- und darmverträglichen Tenside sind z. B. Natriumlaurylsulfat, Dinatriumoctylsulfosuccinat, Natriumalkylsulfoacetat,
Natnumlaurylsarkosinat, Sorbitanester, Diammoniumphosphat, Borax, Glykokoll
sowie enzymatisch wirkende Verbindungen.Evaporation can be loaded with the active ingredient. This loading can also take place by pressing the active ingredient powder into the powder composed of porous particles and then grinding the compact.
To facilitate the transport of the active ingredients and thus to increase their effectiveness, surfactants can be added to the chewing matter, which reduce the surface tension of the diseased tissue. Such gastrointestinal surfactants are z. B. sodium lauryl sulfate, disodium octyl sulfosuccinate, sodium alkyl sulfoacetate, sodium lauryl sarcosinate, sorbitan ester, diammonium phosphate, borax, glycocoll and enzymatically acting compounds.
Die kaubare Matrix enthält bis zu 1%. vorzugsweise 0,2 bis 0.6% medikamentöse Wirkstoffe; z. B. SalbeiölThe chewable matrix contains up to 1%. preferably 0.2 to 0.6% drug active ingredients; z. B. sage oil
« gegen Verschleimung der Atemorgane, Ecchinacea-Extrakt zur Infektionshemmung, Thymol zur Desinfektion, Arnikaöl gegen Entzündungen der Mundschleimhaut, A/ulen gegen Entzündungen der Schleimhäute und gegen Katarrhe, Trihydroxyäthylrutin gegen Husten,«Against mucus in the respiratory organs, ecchinacea extract to inhibit infection, thymol for disinfection, arnica oil against inflammation of the oral mucosa, A / ulen against inflammation of the mucous membranes and against catarrh, trihydroxyethyl rutin against cough,
Rosmarinextrakt gegen MundschHmhautentzündung sowie Ascorbinsäure zur lokalen Stoffwechselsteigering. Rosemary extract against inflammation of the oral mucosa as well as ascorbic acid to increase the local metabolism.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792922670 DE2922670C2 (en) | 1979-06-02 | 1979-06-02 | Chewable dosage form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792922670 DE2922670C2 (en) | 1979-06-02 | 1979-06-02 | Chewable dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2922670A1 DE2922670A1 (en) | 1980-12-11 |
| DE2922670C2 true DE2922670C2 (en) | 1982-09-09 |
Family
ID=6072438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792922670 Expired DE2922670C2 (en) | 1979-06-02 | 1979-06-02 | Chewable dosage form |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2922670C2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
| FR2608156B1 (en) * | 1986-12-12 | 1988-12-30 | Ethypharm Sa | CHEWING GUM FOR FREEING FROM TOBACCO |
| US4822597A (en) * | 1987-07-13 | 1989-04-18 | Warner-Lambert Company | Anesthetic-containing chewing gum compositions |
| US4853212A (en) * | 1987-07-13 | 1989-08-01 | Warner-Lambert Company | Reduced base content chewing gum compositions having anesthetic properties |
| EP0399479B1 (en) * | 1989-05-26 | 1993-08-11 | Gerhard Dr. Gergely | Chewing gum for the disinfection of the mouth and the throat and process for its preparation |
| US5308627A (en) * | 1990-08-07 | 1994-05-03 | Umbdenstock Jr Anthony J | Nutritional supplement for optimizing cellular health |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2435322A1 (en) * | 1974-07-23 | 1976-02-12 | Egwin Leiber | Appts. measuring forces in structures - measuring body deformed by forces transmitted from one structural part to another |
| FR2320083A1 (en) * | 1975-08-07 | 1977-03-04 | Sigma Tau Ind Farmaceuti | Medicated chewing gum - contg. e.g. cetylpyridinium chloride as antiseptic and pref. guaiazulene decongestant |
-
1979
- 1979-06-02 DE DE19792922670 patent/DE2922670C2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2922670A1 (en) | 1980-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69821553T2 (en) | Granule preparation containing simethicone and granulated anhydrous calcium phosphate | |
| DE69803099T2 (en) | COMPOSITION FOR THE TREATMENT OF SMELLING BREATH | |
| DE2611041C2 (en) | ||
| DE69326274T2 (en) | Intraoral device with slow drug release | |
| DE1467961A1 (en) | Delayed release medicament carriers and processes for their manufacture | |
| DE2856393A1 (en) | MEANS FOR TREATING THE CENTRAL VENEER SYSTEM | |
| DE2542158A1 (en) | PHARMACEUTICAL AGENT FOR ADMINISTRATION INTO THE MOUTH AND METHOD OF ITS MANUFACTURING | |
| DE1292783B (en) | Process for the manufacture of a tablet with a depot effect | |
| EP0125634B1 (en) | Use of a secretolytically active substance for the manufacture of a remedy against snoring and for combating snore phenomenon | |
| US20070286821A1 (en) | Composition with activated carbon in oral treatment | |
| DE2922670C2 (en) | Chewable dosage form | |
| DE3338978A1 (en) | Verapamil and gallopamil and their physiologically tolerated salts for application onto the mucous membranes of the mouth, of the naso-pharyngeal space and of the rectum for absorption | |
| EP0399479B1 (en) | Chewing gum for the disinfection of the mouth and the throat and process for its preparation | |
| CH672071A5 (en) | ||
| EP1135147B1 (en) | Method for producing medicaments from plant extracts, in a solid form of administration | |
| RU2608126C1 (en) | Anti-inflammatory composition with prolonged action for treating airway | |
| DE2062715B2 (en) | PROCESS FOR THE MANUFACTURING OF ORAL ADMINISTRATIVE MEDICINAL PREPARATIONS WITH PROTRACTED DELIVERY OF ACTIVE SUBSTANCE AND MEDICINAL PREPARATION | |
| AT414095B (en) | Preparation useful e.g. to treat dry mucous membrane in oral and throat area comprises medical and/or food organic substance, flavor material, mucoadhesive substance, sugar (alcohol) and carrier substance e.g. fat and/or oil | |
| DE2613078A1 (en) | ASTHMA TREATMENT COMPOSITION | |
| DE2458112B2 (en) | Process for the preparation of pellets containing dimethoxanate hydrochloride | |
| DE102010048283A1 (en) | Buyable tablet | |
| EP0341261A1 (en) | Anti-smoking agent | |
| DE102018105197A1 (en) | A MEDICAMENT FOR THE TREATMENT OF COSMETIC PAIN AND A METHOD FOR THE PRODUCTION THEREOF | |
| DE3317558A1 (en) | Oral antisnoring composition | |
| DE3229086A1 (en) | Medicine for coughs and other disorders of the respiratory organs of horses, and feedstuff for horses produced using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8330 | Complete disclaimer |